Sex Health: FDA Approves Yeztugo for HIV Prevention

Person with sterile gloves withdrawing a vaccine solution

In June, the FDA approved Yeztugo, a groundbreaking HIV prevention medication from Gilead. And with it, a new era of sexual health begins.

Yeztugo (which is lenacapavir) si the first long-acting injectable PrEP (pre-exposure prophylaxis) that only needs to be administered twice a year. That's right, just one injection every six months can offer powerful, sustained protection against HIV. For many people, that means fewer pills, fewer reminders, and far fewer barriers to feeling safe and free.

At Liberator, we believe access to sexual wellness is essential to erotic freedom. This milestone isn't just a win for science, it's a win for every body that deserves to love, explore, and connect without fear.

Daily pill carrier with pills sitting on table

What is Yeztugo?

Yeztugo is an injectable form of lenacapavir, a first-in-class HIV capsi inhibitor. Approved for adults and adolescents at risk of HIV through sex, this PrEP option is administered by a healthcare provider once every six months.

Unlike daily PrEP pills or more frequent injections, lenacapavir works by interfering with the HIV capsid, a protein shell essential to the virus' replication. This mechanism allows it to stay active in the body for extended periods, providing long-lasting protection with just two doses a year.

It's discreet. It's low-maintenance. And it opens the door for people who may not have been able, or willing, to stick to a daily medication schedule.

Why This is a Big Deal

Until now, most PrEP options have required consistent daily use (like Truvada or Descovy) or bi-monthly injections (like Apretude). These can be incredibly effective, but they also require discipline, healthcare access, and routines that aren't realistic for everyone.

Yeztugo changes that. By offering long-term protection with minimal upkeep, Yeztugo helps reduce some of the biggest barriers to HIV prevention, like forgetfulness, stigma, access, or simply lifestyle fit. It's a vital new choice for:

People who struggle with or prefer not to take daily pills
Those without regular access to pharmacies or healthcare providers
Individuals seeking more discreet or private options for protection
Anyone who wants one less thing to worry about during sex

The more ways we can protect ourselves, the more freely and fully we can live.

Access, Equity, and What Comes Next

As with any breakthrough, access is everything. While Yeztugo's approval is a cause for celebration, questions around insurance coverage, distribution, and provider availablity still remain. Gilead has stated that the injectable will be available in the US within days of its approval.

For this innovation to reach its full potential, equitable distribution is crucial, especially in communities historically and currently impacted by HIV, including Black and brown queer communuities, trans women, and youth.

Healthcare providers, policymakers, and community advocates will play key roles in ensuring that Yeztugo doesn't just exist but is truly accessible.